The absence of expression of the p16(INK4a) gene product is observed in virtually all mesothelioma tumors and cell lines, whereas wild-type pRB expression is maintained. We have examined the potential therapeutic role of re-expressing the p16(INK4a) gene product in mice with established human mesothelioma xenografts. Experiments using Adp16 treatments in mesothelioma xenografts demonstrated prolonged survival and potential cure following treatment with p16(INK4a)-based gene therapy. These results demonstrate that p16(INK4a) gene transfer may play a therapeutic role in the treatment of mesothelioma.

Original languageEnglish
Pages (from-to)1421-1425
Number of pages5
JournalCancer gene therapy
Issue number11
StatePublished - 2000


  • Cell cycle
  • Gene therapy
  • Mesothelioma
  • Tumor suppressor
  • p16(INK4a)


Dive into the research topics of 'Gene therapy of established mesothelioma xenografts with recombinant p16(INK4a) adenovirus'. Together they form a unique fingerprint.

Cite this